Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
As of April 2026, the BPC-157 FDA approval status remains what it has been for the last two decades: no finished-drug approval, no active Investigational New Drug (IND) application, and no FDA-registered human clinical trials
Always consult with a licensed medical professional to understand what is safe and appropriate for your specific needs
A Certificate of Analysis is available on request for lot-level documentation
Pathway 3 - Lean Mass Through Myostatin Several preclinical studies link MOTS-c to reduced myostatin signaling
After the injection regimen, no further medication was given
That is one reason longer phase 3 trials drew so much interest, since the ceiling had not announced itself yet
US$ 22.05
US$ 26.73
US$ 21.36
US$ 28.42
US$ 28.80
US$ 21.53
